# HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

> **NCT04566445** · PHASE2 · TERMINATED · sponsor: **Gyroscope Therapeutics Limited** · enrollment: 255 (actual)

## Conditions studied

- Dry Age-related Macular Degeneration

## Interventions

- **DRUG:** GT005

## Key facts

- **NCT ID:** NCT04566445
- **Lead sponsor:** Gyroscope Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-28
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 255 (ACTUAL)
- **Why stopped:** Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566445, "HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04566445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*